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Abstract
Endometrial carcinoma is the most common neoplasm of the female genital tract, accounting for
nearly one half of all gynecologic cancers in the Western world. Although intensive research on
pathological phenomena of endometrial cancer is currently going on, but exact cause and biological
aspects of this disease are not well described yet. In addition to well-documented roles of
gonadotropin-releasing hormone (GnRH) in hypopituitary ovarian (HPO) axis, the agonistic or
antagonistic analogs (or both) of GnRH have been shown to inhibit the proliferation of a variety of
human gynecologic cancers. Thus, in the present study, we further examined the possibility that
GnRH induces integrin beta3 and activation of focal adhesion kinase (FAK) through mitogen-
activated protein kinases (MAPKs), ERK1/2 and p38, to inhibit the growth of HEC1A endometrial
cancer cell line. As a result, both GnRH-I and GnRH-II resulted in a significant increase in integrin
beta3 expression and evoked the activation of FAK in a time-dependent manner in these cells. In
addition, these analogs induced an activation of ERK1/2 and p38 MAPK in a time-dependent manner
as downstream pathways of FAK. It appears that GnRH-II has much greater effect on the activation
of FAK, ERK1/2 and p38 compared to GnRH-I in these cells. Further, we demonstrated that the
growth inhibition of HEC1A cells by GnRH-I or GnRH-II is involved in the activation of integrin-
FAK and ERK1/2 and p38 MAPK pathways. Taken together, these results suggest that GnRH may
be involved in the inhibition of endometrial cancer cell growth via activation of integrin beta3 and
FAK as a direct effect. This knowledge could contribute to a better understanding of the
mechanisms implicated in the therapeutic action of GnRH and its biomedical application for the
treatment against endometrial cancer.
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Background
Endometrial carcinoma is the most common neoplasm of
the female genital tract, accounting for nearly one half of
all gynecologic cancers in the Western world. It is esti-
mated that approximately 40,000 new cases of endome-
trial cancer are diagnosed annually in the United States
and about 7,000 women die of this disease, indicating
that endometrial carcinoma is thus the fourth most com-
mon malignancy and the eighth leading cause of cancer-
related death in women [1]. Although intensive research
on pathological phenomena of endometrial cancer is cur-
rently going on, but exact cause and biological aspects of
this disease are not well elucidated yet.
Gonadotropin-releasing hormone (GnRH) is the hypoth-
alamic hormone that mediates reproductive competence
[2,3]. An intermittent GnRH secretion from the hypotha-
lamus acts upon its receptor in the anterior pituitary to
regulate the production and release of two gonadotropins,
luteinizing hormone (LH) and follicle-stimulating hor-
mone (FSH). In addition to reproductive roles of GnRH in
hypo-pituitary ovarian (HPO) axis, GnRH-I, a classical
form of GnRH, has an inhibitory effect on cell growth in
human mammary, ovarian, endometrial, and prostate
tumors and has been implicated as an antiproliferative
factor of gynecologic cancers [4-8]. In particular, the ago-
nistic or antagonistic analogs (or both) of GnRHs have
been shown to inhibit the proliferation of a variety of
human ovarian cancer cell lines in a dose- and time-
dependent manner through activation of extracellular-sig-
nal regulated kinase (ERK) and p38 [9,10]. A second form
of GnRH, GnRH-II, was expressed at the transcriptional
level and GnRH-II induced an inhibition of the ovarian
cancer cell growth in our previous study [11]. In addition,
several in vitro investigations showed that GnRH agonists
and the GnRH antagonist, i.e., cetrorelix, can inhibit the
proliferation of Ishikawa and HEC1A human endometrial
cancer lines and primary cultures of human endometrial
cancer [12-15].
Integrins modulate intracellular signals by growth factor
receptors and play a central role in cell migration. An
integrin heterodimer generally consists of noncovalently
linked  α- and β-subunits, each subunit having a large
extracellular domain, a single membrane spanning
domain and a short, noncatalytic cytoplasmic tail. There
are 18 α and β subunits that form at least 25 distinct pairs
of α and β heterodimers with different ligand specificity
[16,17]. In addition to the previously reported antiprolif-
erative effect, integrin α plays an important role in the
migratory/invasive behavior of melanoma cells expressing
GnRH receptors [18]. In addition to controlling cell adhe-
sion and shape, integrins also transmit signals either by
physical association with several growth factor receptors
or directly through recruitment of non-receptor tyrosine
kinases from the focal adhesion kinase (FAK) and Src fam-
ilies [19]. Although molecular events of integrins have
been recently uncovered in various cell types, their role in
tumorigenesis is yet to be defined. Thus, it is of interest to
examine whether or not integrins and FAK may be
involved in GnRH-induced growth inhibition in endome-
trial cancer cells. In the present study, we further investi-
gated effect of GnRH on the proliferation of HEC1A
endometrial cancer cell line, through integrin and its
downstream effecter molecules, i.e., FAK and mitogen-
activated protein kinases (MAPKs).
Methods
Reagents
A GnRH-I analog, Trp (6), was purchased from Sigma-
Aldrich Ltd. (St Louis, MO, USA). A GnRH-II analog, d-
Arg(6)-Azagly(10)-NH2, was purchased from Peninsula
Laboratories (Belmont, CA). A p38 inhibitor, SB202190,
was purchased from Sigma-Aldrich Ltd.
Antibodies
The polyclonal anti-integrin β3, polyclonal anti-phospho-
FAK (Ser-722), and monoclonal anti-FAK antibodies were
purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). The monoclonal anti-phospho-p44/42 MAPK
(Thr202/Tyr204) and polyclonal anti-p44/42 MAPK anti-
bodies were obtained from Cell Signaling Technology
(Beverly, MA).
Cell culture
A well-characterized human endometrial adenocarci-
noma cell line, HEC1A, was purchased from the American
Type Culture Collection (ATCC, HTB-112; Manassas, VA).
These carcinoma cells were maintained according to the
provider's instruction. The cells were then adjusted to
DMEM/F12 (without phenol red, Invitrogen, Ontario,
Canada) with 10% fetal bovine serum (FBS; Hyclone,
USA). The culture medium was changed every 3 days and
the cells were subdivided every 7 or 8 days. All treatments
were performed after 4 h serum starvation and maintain
serum free condition for appropriate experimental dura-
tions to remove effect of undefined endogenous hor-
mones or cytokines. The cells were cultured on 1: 16
diluted (vol/vol) growth factor-reduced Matrigel (BD,
Franklin Lakes, NJ) coated cell culture dish. The cells were
treated with a specific inhibitor of p38, SB202190 (100
nM), for 20 min after removal of GnRH-1 and -2 contain-
ing medium.
Immunoblot analysis
The cells treated with GnRH-I or -II were washed once
with ice-cold PBS and lysed in 100 μl of in ice-cold RIPA
buffer [150 mm NaCl, 1% Nonidet P-40, 0.5% deoxycho-
late, 0.1% sodium dodecyl sulfate (SDS), 50 mm Tris (pH
7.5), 1 mm phenylmethylsulfonyl fluoride, 10 μg/ml leu-Reproductive Biology and Endocrinology 2009, 7:81 http://www.rbej.com/content/7/1/81
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peptin, and 100 μg/ml aprotinin]. The extracts were
placed on ice for 10 min, collected into a 1.5 ml tube, and
centrifuged for 10 min at 19,000 G. The supernatants were
moved to new tubes, and the concentration of superna-
tants was determined using Bradford assay (Bio-Rad Lab-
oratories, Mississauga, Ontario, Canada). Thirty-five μg of
total protein was mixed with 1/6 volume of sample buffer
(75 mm Tri-HCl of pH 6.8, 15% SDS, 0.15% bromophe-
nol blue, 15% glycerol, and 37.2% 2-mercapthoethanol)
and boiled for 10 min. The sample mixture was run on
10% SDS-PAGE gels (acrylamide : bisacrylamide, 29:1) in
gel running buffer (25 mm Tris/250 mm glycine, pH 8.3/
0.1% SDS) at 100 V for 2.5 h and electrotransferred to a
nitrocellulose membrane (Hybond C, Amersham Phar-
macia Biotech Inc., Oakville, Ontario, Canada) at 100 V
for 1.5 h. The membrane was immunoblotted using pri-
mary antibodies for overnight. After washing three times
with TBS-T (0.1% Tween 20 in Tris-buffered saline) for 15
min, the signals were detected with horseradish peroxi-
dase-conjugated secondary antibody (Amersham Phar-
macia Biotech Inc.), and visualized using the enhanced
chemiluminescence system (Amersham Pharmacia Bio-
tech Inc.). The intensity of signals was quantitated by den-
sitometry (Bio-DocAnalyze, Biometra, Germany).
Proliferation assay
Proliferation assay was performed using [3H]thymidine
incorporation assay as previously described [20]. Briefly,
20,000 cells were seeded in 24-well plates and cultured in
0.5 ml medium. GnRH-I and -II were diluted appropri-
ately with medium, and the cells were cultured 24 h. The
medium was changed after 24 h incubation. After treat-
ment, the cells were then incubated with medium con-
taining 1 μCi [3H]thymidine (0.5 Ci/mmol; Amersham
Pharmacia Biotech Inc.) and collected after 6 h incuba-
tion. The cells were washed three times with PBS and pre-
cipitated with 0.5 ml 10% trichloroacetic acid for 20 min
at 4°C. The precipitate was washed in methanol twice and
solubilized in 0.5 ml of 0.1 N sodium hydroxide. The
radioactivity was measured in the Tri-Carb Liquid Scintil-
lation Analyzer (Model 2100TR, Packard Instrument Co.,
Meriden, CT).
Statistical analysis
Data were subjected to ANOVA test. Each experiment was
repeated three times in duplicate or triplicate. Data are
shown as means of three individual experiments and pre-
sented as the mean ± S.D. Expression level of proteins are
shown as fold changes compared with control levels.
[3H]Thymidine incorporation assay was presented as the
percentage of growth compared with control level and as
the mean ± S.D. 10 measurements were performed per
experiment for each condition. P < 0.05 was considered
statistically significant.
Results
Antiproliferative effect of GnRHs
To determine the effect of GnRH-I and -II on the cell pro-
liferation, the HEC1A cells were treated with increasing
doses of GnRH-I or -II (10 and 100 nM) for 24 h. As seen
in Fig. 1(left panel), treatment with GnRH-I resulted in a
significant decrease in cell proliferation compared to con-
Effect of GnRH-I and GnRH-II on the cell growth Figure 1
Effect of GnRH-I and GnRH-II on the cell growth. HEC1A cells were treated with GnRH-I or GnRH-II analog (10 nM or 
100 nM) for 24 h in serum-free medium. Cell proliferation was determined by 3H-thymidin incorporation assay following treat-
ment with GnRHs. Values are the means of cell number (± S.E.) in triplicates of three independent experiments. a, indicates p 
< 0.05 vs. control (cont).
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trol. After treatment with GnRH-I for 24 h, the inhibitory
effect of proliferation was observed at these concentra-
tions of GnRH-I; 89.8 ± 1.1% at 10 nM and 79.2 ± 2.1%
at 100 nM, respectively. In addition, GnRH-II also
induced cell growth inhibition of HEC1A cells at the doses
of GnRH-II; 80.2 ± 1.8% (10 nM) and 71.2 ± 2.2% (100
nM), respectively (Fig. 1; right panel). These results indi-
cate that HEC1A cell proliferation is dose-dependently
decreased by GnRH-I and -II at these concentrations.
Effect of GnRHs on the expression of integrin β3 subunit
To determine the effect of GnRH-I and -II on the expres-
sion of integrin β3, the HEC1A cells were treated with
GnRH-I or -II (100 nM) for 24 h and then the protein level
of integrin β3 was measured by immunoblot analysis. As
demonstrated in Fig. 2, treatment with GnRH-I resulted in
a significant increase in integrin β3 expression compared
to control. In similar, treatment with GnRH-II induced a
marked increase in the protein level of integrin β3 in these
cells (Fig. 2). These results indicate that the effect of both
GnRH-I and GnRH-II on the inhibition of cell prolifera-
tion may be involved in the expression of integrin β3 pro-
tein in endometrial cancer cells.
Activation of FAK by GnRH-I and -II
To investigate whether GnRH-I and -II induce the activa-
tion of FAK in vitro as a downstream pathway of integrin
signaling, the cells were treated with GnRH-I or -II (100
nM) in a time-dependant manner (0, 5, 10, 15, 20, 30,
and 60 min) following 4 h serum starvation. Following
treatments with GnRH-I or GnRH-II, phosphorylated
form of FAK (pFAK) was measured using a specific anti-
body to phosphorylated FAK by immunoblot analysis. In
addition, total form of FAK was measured by this method
and pFAK was normalized by the expression of total FAK.
As shown in Fig. 3, the treatment with GnRH-I resulted in
a significant increase in the phosphorylation of FAK in
HEC1A cells. It was of interest that GnRH-II induced
much greater expression of pFAK in these cells compared
to GnRH-I as seen in Fig. 3, indicating that GnRH-II may
have a greater effect on the activation of pFAK compared
to that of GnRH-I in HEC1A endometrial cancer cells.
Activation of ERK1/2 by GnRH-I and -II
To investigate whether GnRH-I and -II induce the activa-
tion of ERK1/2, the cells were treated with GnRH-I and -II
(100 nM) in a time-dependant manner (0, 5, 10, 15, 20,
30, and 60 min) after 4 h serum starvation. A phosphor-
ylated form of ERK1/2 (pERK1/2) was measured using a
specific antibody to phosphorylated ERK1/2 by immuno-
blot analysis. In addition, total form of ERK1/2 was meas-
ured and pERK1/2 was normalized by the expression of
total ERK1/2. The treatment with GnRH-I resulted in a sig-
nificant increase in the phosphorylation of ERK1/2 in
HEC1A cells (Fig. 4). In addition, GnRH-II induced much
greater expression of pERK1/2 in these cells compared to
GnRH-I as seen in Fig. 4, indicating that GnRH-II may
have a greater effect on the activation of pERK1/2 com-
pared to that of GnRH-I in HEC1A cells.
Activation of p38 by GnRH-I and -II
To investigate whether GnRH-I and -II induce activation
of p38, the cells were treated with GnRH-I and -II (100
nM) in a time-dependant manner (0, 5, 10, 15, 20, 30,
and 60 min) after 4 h serum starvation. As shown in Fig.
5, GnRH-I significantly phosphorylated p38 MAPK
(pp38) following treatment for 20 min, while GnRH-II
showed much stronger and rapid effect on the activation
Effect of GnRH-I and GnRH-II on the expression of integrin β3 subunit Figure 2
Effect of GnRH-I and GnRH-II on the expression of integrin β3 subunit. HEC1A cells were treated with GnRH-I or 
GnRH-II analog (100 nM) for 24 h in serum-free medium. The protein level of integrin β3 subunit was determined and meas-
ured by immunoblot analysis. Data are shown as means of three individual experiments and presented as the mean ± S.D. a, 
indicates p < 0.05 vs. control (cont).
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of p38 than GnRH-I after 10 to 60 min. To further eluci-
date the direct effect of GnRH-I or -II on the activation of
p38 in HEC1A cells, the cells were pretreated with a p38
inhibitor, SB202190 (100 nM), followed by treatment
with GnRH-I or -II (100 nM) for 20 min. As seen in Fig. 6,
pretreatment with SB202190 reversed GnRH-I or -II
induced phosphorylation of p38, whereas no significant
difference was observed in the cells treated with only
SB202190 itself.
Involvement of p38 pathway in GnRH-I and -II-induced 
cell growth
To further investigate the involvement of p38 MAPK path-
way in the cell growth inhibition by GnRHs, HEC1A cells
were treated with GnRH-I analog (100 nM) or GnRH-II
analog (100 nM) for 24 h in serum-free medium in the
absence or presence of SB202190 (100 nM), a specific
inhibitor of p38, and cell proliferation was determined by
3H-thymidin incorporation assay. The treatment with
GnRH-I or GnRH-II resulted in a marked decrease in cell
growth in these cells, while pretreatment with SB202190
completely abolished the antiproliferative effect of GnRH-
1 or -II as demonstrated in Fig. 7.
Discussion
In addition to the hypothalamus, GnRH-I has also been
localized to the endometrium, placenta, breast, ovary, tes-
tis and prostate [2,21-23]. In the endometrium and myo-
metrium, GnRH receptor has been detected by a
radioligand-binding assay and immunohistochemistry
[21]. Furthermore, Engel et al., (2005) showed that the
cytotoxic GnRH analogues AN-152 and AN-207 inhibit
growth of xenografted HEC1A and RL-95-2 human
endometrial carcinoma cell lines into nude mice [1]. In
the present study, GnRH-I and -II inhibit the cell growth
of HEC1A human endometrial cancer cell line. In addi-
tion, treatment with increasing doses of GnRH-I and -II
(100 nM) resulted in the much stronger inhibition than
10 nM treatment. Thus it would be assumed that HEC1A
cell proliferation is dose-dependently decreased by
GnRH-I and -II at these concentrations.
Effect of GnRH-I and GnRH-II on the activation of FAK Figure 3
Effect of GnRH-I and GnRH-II on the activation of FAK. HEC1A cells were treated with GnRH-I or GnRH-II (100 nM) 
in a time-dependent manner. Phosphorylation of FAK was determined by Western blot analysis following treatment with 
GnRHs. Data are shown as means of three individual experiments and presented as the mean ± S.D. a, indicates p < 0.05 vs. 
control (cont). The white bars indicate GnRH-I treatment while gray bars indicate GnRH-II treatment.
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A further support for GnRH influence on cell proliferation
was provided in a previous study [24]. Davidson et al.
demonstrated that activation of the GnRH receptor
resulted in both cell adhesion and cytoskeletal remode-
ling and GnRH (10-7  M) increased adhesiveness of
HEK293 cells overexpressing GnRH receptor. A cytoskele-
tal remodeling was dependent on FAK, c-Src, ERK and Rac
and independent from the classic phospholipase C signal-
ing pathway [24]. GnRH-dependent intracellular signal-
ing events for downstream of PKC have been
characterized [25]. Several groups have demonstrated that
GnRH receptor occupancy resulted in the activation of
ERK and c-jun N-terminal protein kinase [26,27], mem-
bers of the MAPK superfamily. GnRH activation of the
JNK cascade is dependent on the low molecular weight
GTP-binding protein, Cdc42 [26]. In addition to the ERK
and JNK cascades, the MAPK superfamily includes the p38
kinase pathway [20,27,28] reported that GnRH can stim-
ulate activation of the p38 kinase pathway. Activation of
the p38 kinase by GnRH requires PKC, suggesting that
GnRH-induced p38 MAPK activation may selectively con-
tribute to the regulation of c-fos protooncogene expres-
sion, but not c-jun or the glycoprotein hormone α-subunit
gene. Recently, we demonstrated that binding of GnRH-I
(a classical form of GnRH) and GnRH-II (a second form
of GnRH) to the GnRH-I receptor activates ERK1/2
through a PKC-dependent pathway and is essential for
GnRH-induced anti-proliferation of ovarian cancer cells
[20]. In this study, we clearly demonstrated that GnRH-I
or GnRH-II resulted in a significant increase in the phos-
phorylation of ERK1/2 and p38 in HEC1A cells, suggest-
ing these MAPKs are involved in GnRH-I or GnRH-II
induced cell growth inhibition of endometrial cancer
cells. It is of interest that GnRH-II induced much greater
expression of pERK1/2 or pp38 in these cells compared to
GnRH-I, suggesting that GnRH-II may have a greater effect
on the activation of pERK1/2 or pp38 compared to that of
GnRH-I in HEC1A endometrial cancer cells.
Immunohistochemical studies for human endometrium
throughout the menstrual cycle revealed a sudden
increase in β3-integrin expression in luminal and glandu-
lar epithelial cells at mid secretory phase [29,30]. It was of
interest that the overexpression of integrin β3 subunit
suppressed tumor growth [31]. So far, ligand binding and
clustering are known as an important step for full integrin
function and the recruitment of downstream signal trans-
duction cascade molecules [32]. Numerous studies have
Effect of GnRH-I and GnRH-II on the activation of ERK1/2 Figure 4
Effect of GnRH-I and GnRH-II on the activation of ERK1/2. HEC1A cells were treated with GnRH-I or GnRH-II (100 
nM) in a time-dependent manner. Phosphorylation of ERK1/2 was determined by Western blot analysis following treatment 
with GnRHs. The error bars represent the mean ± S.D. from three independent experiments. a, indicates p < 0.05 vs. control 
(cont).). The white bars indicate GnRH-I treatment while gray bars indicate GnRH-II treatment.
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
C o n t 51 01 5 2 0 3 06 0 m i n
GnRH-I
Total ERK
pERK1/2
C o n t 51 01 5 2 0 3 06 0 m i n
GnRH-II
Total ERK
pERK1/2
Cont 5 10 15 20 30 60
Treatment with GnRHs (min)
a
aa
a
a
a a
a
a
GnRH-I
GnRH-IIReproductive Biology and Endocrinology 2009, 7:81 http://www.rbej.com/content/7/1/81
Page 7 of 10
(page number not for citation purposes)
Effect of GnRH-I and GnRH-II on the activation of p38 Figure 5
Effect of GnRH-I and GnRH-II on the activation of p38. HEC1A cells were treated with GnRH-I or GnRH-II (100 nM) in 
a time-dependent manner. Phosphorylation of ERK1/2 was determined by Western blot analysis following treatment with 
GnRHs. The error bars represent the mean ± S.D. from three independent experiments. a, indicates p < 0.05 vs. control 
(cont).). The white bars indicate GnRH-I treatment while gray bars indicate GnRH-II treatment.
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Effect of SB202190 on the GnRH-I-induced or GnRH-II-induced p38 activation Figure 6
Effect of SB202190 on the GnRH-I-induced or GnRH-II-induced p38 activation. HEC1A cells were treated with 
GnRH-I or GnRH-II for 20 min in serum-free medium in the absence or presence of SB202190 (100 nM), a specific inhibitor of 
p38, to further elucidate the direct effect of GnRH-I or -II on the activation of p38 in HEC1A cells.
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suggested that β3 and αVβ3 integrins are overexpressed in
solid tumors, and that this overexpression plays a role in
tumor growth and invasion. It was speculated that β3
overexpression in glioma cells suppresses, rather than
stimulates, glioma growth, but that this occurs exclusively
in vivo and not in vitro [31]. Previous studies revealed that
the growth and metastasis of transplanted tumors in mice
showed lacking of specific cell adhesion receptors,
integrins or selectins [20,33,34]. In addition, integrin β3
or selectin null mice showed increased primary tumor
growth in vivo [35]. In this study, GnRH-I and -II can
increase integrin β3 expression in HEC1A cells in vitro,
suggesting that GnRH may be a direct regulator of integrin
β3 expression and play a pivotal role as a growth inhibitor
by regulating its expression in endometrial cancer cells.
It is also apparent that the GnRH receptor, like many
other heptahelical G protein-coupled receptors, can also
activate monomeric G protein molecules [36]. The activa-
tion of these monomeric pathways has been shown to
mediate important effects of GnRH in gonadotropes such
as control of gonadotropin hormone subunit transcrip-
tion [26]. A previous study has also shown that in many
cell types, stimulation of Gi- or Gq-coupled receptors
causes FAK activation [37-39]. FAK also has been reported
to bind to the intracellular regions of β-integrin subunits,
and to play a pivotal role as a signal integrator down-
stream of cell-ECM interactions and other receptor and
non-receptor tyrosine kinases [40]. In this study, we dem-
onstrated that GnRH induced FAK phosphorylation in
HEC1A endometrial cancer cells. GnRH-I induced FAK
phosphorylation at 5 min and decreased within 30 min.
On the other hand, GnRH-II increased FAK phosphoryla-
tion after 5 min and reached maximum rate at 20 min fol-
lowing treatment. Based on these observations, it can be
suggested that activation of FAK in HEC1A cells by GnRH
is mediated by elevated integrin β3 expression. FAK has
known to be a regulator of ERK activation in many cell
types [24,41]. Phosphorylation of ERK was induced by
treatment with GnRH-I and -II in this study as shown in
the Results. Many substrates of ERK are localized in the
nucleus and cytosol. In addition, ERK phosphorylates
many cytoskeletal elements and is important for the deter-
mination of cellular morphology, and can serve as anchor
proteins that direct ERK to their proper locations. In this
study, we did not see any changes of cellular morphology
and adhesion property in these cells (Data not shown).
Thus, we suggest that ERK might interact with nuclear sub-
Effect of SB202190 on the GnRH-I- or GnRH-II-induced inhibition of cell growth Figure 7
Effect of SB202190 on the GnRH-I- or GnRH-II-induced inhibition of cell growth. HEC1A cells were treated with 
GnRH-I or GnRH-II for 24 h in serum-free medium in the absence or presence of SB202190 (100 nM), a specific inhibitor of 
p38. Cell proliferation was determined by 3H-thymidin incorporation assay following treatment with GnRHs. Values are the 
mean cell number (± S.E.) from three independent experiments. Values are the means of cell number (± S.E.) in triplicates of 
three independent experiments. a, indicates p < 0.05 vs. control (cont); b, indicates p < 0.05 vs. GnRH-I or GnRH-II treatment 
only.
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strates such as transcriptional factors rather than cytoplas-
mic substrates such as cytoskeletal elements.
In our previous study, we demonstrated that the antipro-
liferative effect of GnRH-II in ovarian cancer cells may
involve p38 MAPK, which led us to investigate the role of
other MAPK family members [9]. To investigate the signal
pathway involved in the antiproliferative effect by GnRH-
I and -II, the activation of p38 in HEC1A cells was exam-
ined by immunoblot analysis using the phospho-specific
MAPK antibody after treatment with GnRH-I and -II. The
p38 MAPK is activated by the phosphorylation on tyro-
sine 180 and tyrosine 182 in the activation loop and mod-
ulates cell cycle for the response to environmental stress,
hormones, ligands that bind to G protein-coupled recep-
tors, and inflammatory cytokines [42]. In this study, we
observed that GnRH-II (100 nM) induced the activation
of p38 MAPK in as early as 10 min, which is in agreement
with a previous study performed in OVCAR-3 cells [20],
while GnRH-I showed weaker and delayed effect than
GnRH-II. Furthermore, the activation of p38 MAPK was
completely blocked by SB203580 (100 nM), a specific
inhibitor of p38 MAPK, in this study. In addition to this,
antiproliferative effect of GnRH was reversed by pretreat-
ment of SB203580 (100 nM). Activation of p38 MAPK
can also induce apoptotic cell death, but we did not detect
any evidence of apoptosis in HEC1A cells following treat-
ment with GnRH (Data not shown). This result was sup-
ported by previous data using HEC1A cells, indicating
that GnRH analogs did not affect cell viability after treat-
ment [43]. It can be speculated that effects of Antide, a
GnRH receptor antagonist, may have some agonistic or
antagonistic effect on the cell proliferation of endometrial
cancer cells. Thus, Antide was treated with GnRH or alone
for same duration abovementioned in HEC1A cells. In
this study, we failed to observe any agonistic or antagonis-
tic effect of Antide on the proliferation of HEC1A cells
(data not shown). It was reported that Antide showed an
agonistic effect on HEC1A cell proliferation only after 6-
day treatment, while no significant antiproliferative effect
was observed at earlier times [43]. This result indicates
that Antide may have a lower affinity to GnRH receptors
than GnRH analogs. So far, an anti-tumor effect of GnRH
analogs has been reported. We speculated that both
GnRH-I and -II analogs resulted in an inhibition of
human endometrial cancer cell proliferation and this
effect is mediated by GnRH receptor and its related signal
transduction molecules.
In summary, both GnRH-I and GnRH-II resulted in a sig-
nificant increase in integrin β3 expression and evoked the
activation of FAK in a time-dependent manner in HEC1A
cells. In addition, these analogs induced an activation of
ERK1/2 and p38 MAPK in a time-dependent manner as
downstream pathways of FAK. It appears that GnRH-II has
much greater effect on FAK, ERK1/2 and p38 MAPK than
GnRH-I in these cells. Further, the growth inhibition of
HEC1A cells by GnRH-I or GnRH-II may be involved in
the activation of integrin-FAK, ERK1/2 and p38 MAPK
pathways. Thus, these results suggest that GnRH may have
an effect on the inhibition of cell growth of endometrial
cancer cells through a direct pathway. This knowledge
could contribute to a better understanding of the mecha-
nisms implicated in the action of GnRH and its biomedi-
cal application for the treatment against endometrial
cancer. Although this study showed an inhibitory effect of
GnRH on endometrial cancer cell growth, a further study
is essential to reveal the ultimate cellular change and effect
of GnRH on endometrial cancer cells.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DWP carried out the overall experiments to complete this
study and drafted the manuscript. KCC performed experi-
ments, in part, and drafted and finalized the manuscript.
CDM participated in the design of the study and per-
formed the statistical analysis. PCKL conceived of the
study, and participated in its design and coordination and
helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported by the Canadian Institutes for Health Research 
and the Canadian Foundation for Women's Health to PCKL. PCKL was the 
recipient of a Distinguished Scholar Award from the Michael Smith Foun-
dation for Health Research. In addition, this work was supported by the 
Post-doctoral Fellowship Program of Korea Science & Engineering Founda-
tion (KOSEF) to DWP and the National Cancer Institute of Canada (NCIC) 
to KCC.
References
1. Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G: Effec-
tive treatment of experimental human endometrial cancers
with targeted cytotoxic luteinizing hormone-releasing hor-
mone analogues AN-152 and AN-207.  Fertil Steril 2005,
83(Suppl 1):1125-1133.
2. Wierman ME, Bruder JM, Kepa JK: Regulation of gonadotropin-
releasing hormone (GnRH) gene expression in hypothalamic
neuronal cells.  Cell Mol Neurobiol 1995, 15(1):79-88.
3. Neill JD: GnRH and GnRH receptor genes in the human
genome.  Endocrinology 2002, 143(3):737-743.
4. Santen RJ: Clinical review 37: Endocrine treatment of prostate
cancer.  J Clin Endocrinol Metab 1992, 75(3):685-689.
5. Savino L, Baldini B, Susini T, Pulli F, Antignani L, Massi GB: GnRH
analogs in gynecological oncology: a review.  J Chemother 1992,
4(5):312-320.
6. Schally A, Nagy A: Targeted cytotoxic analogs of luteinizing
hormone-releasing hormone: a reply.  Eur J Endocrinol 2001,
144(5):559.
7. Schally AV: Luteinizing hormone-releasing hormone analogs:
their impact on the control of tumorigenesis.  Peptides 1999,
20(10):1247-1262.
8. Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B,
Emons G: Antiproliferative effects of the GnRH antagonist
cetrorelix and of GnRH-II on human endometrial and ovar-Reproductive Biology and Endocrinology 2009, 7:81 http://www.rbej.com/content/7/1/81
Page 10 of 10
(page number not for citation purposes)
ian cancer cells are not mediated through the GnRH type I
receptor.  Eur J Endocrinol 2004, 151(1):141-149.
9. Kim KY, Choi KC, Park SH, Auersperg N, Leung PC: Extracellular
signal-regulated protein kinase, but not c-Jun N-terminal
kinase, is activated by type II gonadotropin-releasing hor-
mone involved in the inhibition of ovarian cancer cell prolif-
eration.  The Journal of clinical endocrinology and metabolism 2005,
90(3):1670-1677.
10. Kim KY, Choi KC, Park SH, Chou CS, Auersperg N, Leung PC: Type
II gonadotropin-releasing hormone stimulates p38 mitogen-
activated protein kinase and apoptosis in ovarian cancer
cells.  The Journal of clinical endocrinology and metabolism 2004,
89(6):3020-3026.
11. Choi KC, Auersperg N, Leung PC: Expression and antiprolifera-
tive effect of a second form of gonadotropin-releasing hor-
mone in normal and neoplastic ovarian surface epithelial
cells.  The Journal of clinical endocrinology and metabolism 2001,
86(10):5075-5078.
12. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD, Schally
AV: High affinity binding and direct antiproliferative effects
of luteinizing hormone-releasing hormone analogs in human
endometrial cancer cell lines.  J Clin Endocrinol Metab 1993,
77(6):1458-1464.
13. Noci I, Borri P, Bonfirraro G, Chieffi O, Arcangeli A, Cherubini A,
Dabizzi S, Buccoliero AM, Paglierani M, Taddei GL: Longstanding
survival without cancer progression in a patient affected by
endometrial carcinoma treated primarily with leuprolide.  Br
J Cancer 2001, 85(3):333-336.
14. Grundker C, Gunthert AR, Westphalen S, Emons G: Biology of the
gonadotropin-releasing hormone system in gynecological
cancers.  Eur J Endocrinol 2002, 146(1):1-14.
15. Grundker C, Volker P, Emons G: Antiproliferative signaling of
luteinizing hormone-releasing hormone in human endome-
trial and ovarian cancer cells through G protein alpha(I)-
mediated activation of phosphotyrosine phosphatase.  Endo-
crinology 2001, 142(6):2369-2380.
16. Hood JD, Cheresh DA: Role of integrins in cell invasion and
migration.  Nat Rev Cancer 2002, 2(2):91-100.
17. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW,
Rossjohn J, Price JT: Bimolecular interaction of insulin-like
growth factor (IGF) binding protein-2 with alphavbeta3 neg-
atively modulates IGF-I-mediated migration and tumor
growth.  Cancer Res 2004, 64(3):977-984.
18. Moretti RM, Montagnani Marelli M, Mai S, Limonta P: Gonadotro-
pin-releasing hormone agonists suppress melanoma cell
motility and invasiveness through the inhibition of alpha3
integrin and MMP-2 expression and activity.  Int J Oncol 2008,
33(2):405-413.
19. Stupack DG, Cheresh DA: Get a ligand, get a life: integrins, sig-
naling and cell survival.  J Cell Sci 2002, 115(Pt 19):3729-3738.
20. Lee GS, Choi KC, Kim HJ, Jeung EB: Effect of genistein as a selec-
tive estrogen receptor beta agonist on the expression of Cal-
bindin-D9k in the uterus of immature rats.  Toxicol Sci 2004,
82(2):451-457.
21. Clayton RN, Catt KJ: Gonadotropin-releasing hormone recep-
tors: characterization, physiological regulation, and relation-
ship to reproductive function.  Endocr Rev 1981, 2(2):186-209.
22. Huirne JA, Lambalk CB: Gonadotropin-releasing-hormone-
receptor antagonists.  Lancet 2001, 358(9295):1793-1803.
23. Limonta P, Moretti RM, Marelli MM, Motta M: The biology of gona-
dotropin hormone-releasing hormone: role in the control of
tumor growth and progression in humans.  Front Neuroendocri-
nol 2003, 24(4):279-295.
24. Davidson L, Pawson AJ, Millar RP, Maudsley S: Cytoskeletal reor-
ganization dependence of signaling by the gonadotropin-
releasing hormone receptor.  J Biol Chem 2004,
279(3):1980-1993.
25. Sundaresan S, Colin IM, Pestell RG, Jameson JL: Stimulation of
mitogen-activated protein kinase by gonadotropin-releasing
hormone: evidence for the involvement of protein kinase C.
Endocrinology 1996, 137(1):304-311.
26. Levi NL, Hanoch T, Benard O, Rozenblat M, Harris D, Reiss N, Naor
Z, Seger R: Stimulation of Jun N-terminal kinase (JNK) by
gonadotropin-releasing hormone in pituitary alpha T3-1 cell
line is mediated by protein kinase C, c-Src, and CDC42.  Mol
Endocrinol 1998, 12(6):815-824.
27. Roberson MS, Zhang T, Li HL, Mulvaney JM: Activation of the p38
mitogen-activated protein kinase pathway by gonadotropin-
releasing hormone.  Endocrinology 1999, 140(3):1310-1318.
28. Cobb MH, Goldsmith EJ: How MAP kinases are regulated.  J Biol
Chem 1995, 270(25):14843-14846.
29. Lessey BA, Castelbaum AJ, Buck CA, Lei Y, Yowell CW, Sun J: Fur-
ther characterization of endometrial integrins during the
menstrual cycle and in pregnancy.  Fertil Steril 1994,
62(3):497-506.
30. Lessey BA, Damjanovich L, Coutifaris C, Castelbaum A, Albelda SM,
Buck CA: Integrin adhesion molecules in the human
endometrium. Correlation with the normal and abnormal
menstrual cycle.  J Clin Invest 1992, 90(1):188-195.
31. Kanamori M, Berg SR Vanden, Bergers G, Berger MS, Pieper RO:
Integrin beta3 overexpression suppresses tumor growth in a
human model of gliomagenesis: implications for the role of
beta3 overexpression in glioblastoma multiforme.  Cancer Res
2004, 64(8):2751-2758.
32. Hato T, Pampori N, Shattil SJ: Complementary roles for recep-
tor clustering and conformational change in the adhesive
and signaling functions of integrin alphaIIb beta3.  J Cell Biol
1998, 141(7):1685-1695.
33. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A:
Heparin and cancer revisited: mechanistic connections
involving platelets, P-selectin, carcinoma mucins, and tumor
metastasis.  Proc Natl Acad Sci USA 2001, 98(6):3352-3357.
34. Borsig L, Wong R, Hynes RO, Varki NM, Varki A: Synergistic
effects of L- and P-selectin in facilitating tumor metastasis
can involve non-mucin ligands and implicate leukocytes as
enhancers of metastasis.  Proc Natl Acad Sci USA 2002,
99(4):2193-2198.
35. Taverna D, Moher H, Crowley D, Borsig L, Varki A, Hynes RO:
Increased primary tumor growth in mice null for beta3- or
beta3/beta5-integrins or selectins.  Proc Natl Acad Sci USA 2004,
101(3):763-768.
36. Kraus S, Naor Z, Seger R: Intracellular signaling pathways medi-
ated by the gonadotropin-releasing hormone (GnRH) recep-
tor.  Arch Med Res 2001, 32(6):499-509.
37. Hordijk PL, Verlaan I, van Corven EJ, Moolenaar WH: Protein tyro-
sine phosphorylation induced by lysophosphatidic acid in
Rat-1 fibroblasts. Evidence that phosphorylation of map
kinase is mediated by the Gi-p21ras pathway.  J Biol Chem 1994,
269(1):645-651.
38. Luttrell LM, Daaka Y, Della Rocca GJ, Lefkowitz RJ: G protein-cou-
pled receptors mediate two functionally distinct pathways of
tyrosine phosphorylation in rat 1a fibroblasts. Shc phospho-
rylation and receptor endocytosis correlate with activation
of Erk kinases.  J Biol Chem 1997, 272(50):31648-31656.
39. Rodriguez-Fernandez JL: Why do so many stimuli induce tyro-
sine phosphorylation of FAK?  Bioessays 1999, 21(12):1069-1075.
40. Brunton VG, MacPherson IR, Frame MC: Cell adhesion receptors,
tyrosine kinases and actin modulators: a complex three-way
circuitry.  Biochim Biophys Acta 2004, 1692(2–3):121-144.
41. Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S, Hahn KM:
Vinculin modulation of paxillin-FAK interactions regulates
ERK to control survival and motility.  J Cell Biol 2004,
165(3):371-381.
42. Johnson GL, Lapadat R: Mitogen-activated protein kinase path-
ways mediated by ERK, JNK, and p38 protein kinases.  Science
2002, 298(5600):1911-1912.
43. Borri P, Coronnello M, Noci I, Pesciullesi A, Peri A, Caligiani R, Maggi
M, Torricelli F, Scarselli G, Chieffi O, Mazzei T, Mini E: Differential
inhibitory effects on human endometrial carcinoma cell
growth of luteinizing hormone-releasing  hormone ana-
logues.  Gynecol Oncol 1998, 71(3):396-403.